within Pharmacolibrary.Drugs.ATC.V;

model V04CD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 1500 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metyrapone is an inhibitor of adrenal steroidogenesis by blocking 11-β-hydroxylase, leading to decreased cortisol synthesis. It is primarily used as a diagnostic agent for hypothalamic-pituitary-adrenal (HPA) axis disorders and, less commonly, as a treatment for Cushing's syndrome. It has been used clinically for many years and remains available as a diagnostic drug.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults following oral administration; no comprehensive human population PK models published in indexed literature.</p><h4>References</h4><ol><li><p>Murata, H, et al., &amp; Otagiri, M (2016). Oral pharmacokinetics and in-vitro metabolism of metyrapone in male rats. <i>The Journal of pharmacy and pharmacology</i> 68(8) 970–979. DOI:<a href=&quot;https://doi.org/10.1111/jphp.12560&quot;>10.1111/jphp.12560</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27265478/&quot;>https://pubmed.ncbi.nlm.nih.gov/27265478</a></p></li><li><p>Noe, S, et al., &amp; Neu, B (2017). Dynamics of Adrenocorticotropin after Application of Metyrapone. <i>Experimental and clinical endocrinology &amp; diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association</i> 125(1) 53–56. DOI:<a href=&quot;https://doi.org/10.1055/s-0042-117832&quot;>10.1055/s-0042-117832</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27750352/&quot;>https://pubmed.ncbi.nlm.nih.gov/27750352</a></p></li><li><p>Perucca, E (1982). Pharmacokinetic interactions with antiepileptic drugs. <i>Clinical pharmacokinetics</i> 7(1) 57–84. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198207010-00004&quot;>10.2165/00003088-198207010-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7042173/&quot;>https://pubmed.ncbi.nlm.nih.gov/7042173</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V04CD01;
